Apricus Biosciences - könnte interessant werden

Es wird heute wieder  fliegen!!!!

SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Vitaros® in Italy by Bracco SpA. Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"), is also marketed under the trademark Vytaros® in Belgium and Virirec(TM) in Spain. This is the seventh country in the European Union in which the product has been launched, including France, Italy, Germany, the United Kingdom, Spain, Belgium and Sweden. In total, Vitaros is currently approved under the European Decentralized Procedure ("DCP") in twenty-two countries, of which fourteen have further approved Vitaros for commercialization at the national phase level of the DCP approval process.

Richard Pascoe, Chief Executive Officer of Apricus, commented, "We are pleased to announce Bracco's launch of Vitaros, the first on-demand topical treatment, in Italy, Europe's second largest ED treatment market which Bracco estimates to be approximately $135 million. As another contributor towards the positive momentum of commercialization by our partners, which recently produced 103% growth in units quarter over quarter, Bracco plans to implement a strong promotional strategy targeted at physicians across Italy. With this news, the product is now launched in the five largest markets in Europe."

In December 2010, Apricus signed an exclusive license agreement with Bracco to market Vitaros, in Italy, Vatican City and San Marino (the "Territory"). Under the terms of the agreement, Apricus has received $1.3 million in up-front and milestone payments from Bracco. Apricus is also eligible to receive milestone payments on future sales, plus double-digit tiered royalties based on Bracco's net sales of the product in the Territory.  In exchange, Bracco has the exclusive right to commercialize Vitaros in the Territory.  In addition, Bracco has agreed to certain minimum marketing commitments for Vitaros.

die News von gestern ist wohl nicht so toll ( angekommen ) !? oder weshalb fällt die heute so stark ???  

Im April erwartet

https://clinicaltrials.gov/ct2/show/record/...term=Apricus&rank=2

Laut der neusten Präsentation vom 08.02.2016:

Fispemifene top-line Phase 2b data in Q1 2016 

http://phx.corporate-ir.net/...NoaWxkSUQ9MzIyMTk4fFR5cGU9MQ==&t=1

werden morgen veröffentlicht. Sarissa besitzt nun über 30 % Anteile an Apricus:

http://secfilings.nasdaq.com/...FA&RcvdDate=3%2F7%2F2016&pdf=wir

http://ir.apricusbio.com/...c=118007&v=203&d=1&id=2147303

... sollten die Tage nun released werden. Der Anstieg könnte ein positiver Vorbote sein. Schon $1,28 AH in Übersee.
LG, biotech

http://ir.apricusbio.com/...c=118007&v=203&d=1&id=2151055

Anyone listen to today's webcast? NDA for Vitaros US target in Q3 2016, with hope for approval 6 months hence Reduce spending by 30% by streamlining Capital needs greatly reduced Operating income needs and length of sustainability will be recalculated  No mention of milestones   RayVa orphan status feedback will be pursued, forgot what Pascoe said about timeframe for 2B Organic growth of Vitaros in European countries already launched Grow Vitaros Europe with additional launches in approved countries and seek approval in additional countries Well this certainly was bad news today, but I came here for Vitaros, so I guess I'll just have to suck it up and see how the original instincts line up...

http://www.siliconinvestor.com/readmsg.aspx?msgid=30520192

auf die nächsten Ereignisse:

http://ir.apricusbio.com/...x.zhtml?c=118007&p=irol-presentations

Apricus Biosciences, Inc. Wednesday said plans to prioritize the Vitaros commercial and regulatory activities and to deprioritize all other pipeline programs. The company expects 30 percent reduction in staff and cash-based operating expenses. It will also cut short the size of the director board and cash compensation.

http://www.nasdaq.com/article/...ff-operating-expenses-20160406-00250

Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia

http://www.nasdaq.com/press-release/...rmaceuticals-in-20160725-00181

Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
http://www.nasdaq.com/press-release/...-dysfunction-in-20160727-00295

Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals

http://www.nasdaq.com/press-release/...uthorization-to-20160810-00205

Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals

http://www.nasdaq.com/press-release/...g-authorization-20160815-00151

www.finanznachrichten.de/...-president-general-counsel-252.htm

da war ich mal wieder schlau!!!!

http://phx.corporate-ir.net/...NoaWxkSUQ9MzY2NjgyfFR5cGU9MQ==&t=1

die Party geht weiter!!!!!!

Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals

http://www.nasdaq.com/press-release/...pharmaceuticals-20170308-01117

sehr gute Gewinne mit der Aktie gemacht.
Lege trotzdem noch mal nach!!!
Keine Kaufe.....

von gestern wieder abgeben. Bin ab heute trotzdem in der aktie investiert.  

endpts.com/...-fda-rejection-of-erectile-dysfunction-therapy/